SMALL-CELL LUNG CANCER IN 2016: Shining light on novel targets and therapies

    loading  Checking for direct PDF access through Ovid

Abstract

In 2016, the pace of biological insights into small-cell lung cancer (SCLC) was reflected in new treatment approaches that have suggested meaningful clinical benefit to patients. We focus on three highlights of 2016: preclinical studies defining NFIB as a putative driver of metastasis, and two clinical studies; one that assessed the efficacy of an agent targeting the Notch ligand DLL3, and the other that explored T-cell checkpoint-blockade therapies targeting PD-1 and CTLA-4.

Related Topics

    loading  Loading Related Articles